FHLC vs. BBH: Which Healthcare ETF Is the Better Buy?

Fidelity MSCI Health Care Index ETF (FHLC) is pitched as a lower-risk alternative to VanEck Biotech ETF (BBH), citing a much lower 0.08% expense ratio vs 0.35%. Over five years, FHLC reportedly delivered higher total growth ($1,322 vs $1,066 on $1,000) with a smaller maximum drawdown (-17.73% vs -39.86%) while holding 338 healthcare stocks versus BBH’s 25 biotech names. The article also notes higher trailing dividend yield for FHLC at 1.40% versus BBH at 0.51%.

Analysis

This is less a healthcare call than a packaging call: the lower-fee, broader vehicle is the one institutional allocators are most likely to use for core exposure, while the concentrated biotech sleeve is a satellite bet on binary outcomes. That matters because ETF flows are sticky and mechanically favor the largest weights, so LLY, JNJ, and ABBV should capture the first-order bid if healthcare is used as a defensive equity allocation. BBH’s concentration makes it more sensitive to one or two disappointments, which can suppress multiple expansion even when the underlying sector backdrop is constructive.

The near-term setup favors FHLC over BBH over 1-3 months if the market remains in a “steady growth, selective biotech” regime. Biotech only really wins when catalyst density is high: positive FDA reads, M&A, or falling real rates that extend duration for pre-profit names. Absent that, BBH’s higher volatility becomes a handicap rather than an edge, and drawdown-sensitive mandates will continue preferring the broader basket.

Contrarian angle: the consensus focus on BBH’s upside ignores the friction of higher turnover, lower income, and tighter risk limits in real portfolios. The overdone move is chasing the higher trailing return without accounting for mandate constraints; the underappreciated trade is that broad healthcare can outperform on a risk-adjusted basis even if biotech headlines stay noisy. The thesis breaks if biotech-specific catalysts accelerate or if a small-cap/risk-on rotation re-rates the entire subindustry faster than large-cap healthcare.

Key Decisions for Investors

• Long FHLC / short BBH for 1-3 months as a relative-value expression of lower fee drag and lower drawdown risk; target modest outperformance, with a stop if BBH outperforms on a clear biotech catalyst wave.
• Use FHLC as the default healthcare core holding rather than a biotech-only sleeve; the trade is quality of exposure, not just sector beta.
• Within healthcare, overweight passive-flow beneficiaries LLY, JNJ, and ABBV over BBH constituents for the next quarter, since broad-ETF allocations are likely to concentrate into the largest weights.
• Do not chase BBH without a catalyst calendar; only add on a confirmed FDA/M&A window or a decisive decline in real yields that can re-open duration appetite for biotech.
• Watch for a biotech M&A surge or a sharp risk-on small-cap rally as the main falsifier of the FHLC-over-BBH relative view.